New Long-Term Data for Genentech's Vabysmo Show Sustained Retinal Drying and Vision Improvements in Retinal Vein Occlusion (RVO)Business Wire • 02/01/24
New long-term data for Roche's Vabysmo show sustained retinal drying and vision improvements in retinal vein occlusion (RVO)GlobeNewsWire • 02/01/24
[Ad hoc announcement pursuant to Art. 53 LR] Roche exceeds guidance and achieves sales growth of 1% (CER) for 2023 despite sharp COVID-19 sales declineGlobeNewsWire • 02/01/24
European Commission approves Roche's Tecentriq SC, the EU's first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer typesGlobeNewsWire • 01/16/24
MOMA Therapeutics Announces Five-Year Discovery Collaboration with Roche Focused on Critical Cancer DependenciesBusiness Wire • 01/04/24
Remix Therapeutics Enters Collaboration with Roche for the Discovery and Development of Small Molecule Therapeutics Modulating RNA ProcessingPRNewsWire • 01/03/24
Roche enters into a definitive agreement to acquire LumiraDx's Point of Care technology combining multiple diagnostic modalities on a single platformGlobeNewsWire • 12/29/23
Weighing Their Chances: 5 Leading Healthcare Companies Fight for Market Share in the $100 Billion Weight-Loss IndustryThe Motley Fool • 12/21/23
Five obesity-drug trends to watch in 2024: Who can compete with Eli Lilly and Novo Nordisk?Market Watch • 12/20/23
This Big Pharma Is Teaming Up With Nvidia to Make Drugs With AI. Here's What You Need to KnowThe Motley Fool • 12/20/23
FDA grants priority review to Xolair (omalizumab) for children and adults with food allergies based on positive National Institutes of Health phase III study resultsGlobeNewsWire • 12/19/23
FDA Grants Priority Review to Xolair (omalizumab) for Children and Adults With Food Allergies Based on Positive National Institutes of Health Phase III Study ResultsBusiness Wire • 12/19/23